Y-mAbs Therapeutics (YMAB) Misses Q3 EPS by 6c
Tweet
Share
E-mail
Get Alerts YMAB Hot Sheet
Join SI Premium – FREE
Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q3 EPS of ($0.66), $0.06 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $9 million versus the consensus estimate of $10.87 million.
For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- L3Harris CEO steps down amid conduct review, shares drop
- Vivos Therapeutics (VVOS) Tops Q2 EPS by 6c
- Cue Biopharma, Inc. (CUE) Misses Q2 EPS by 2054c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
